At the outer-jacket coextrusion stage of a multi-layer intravascular catheter shaft, a 20 mm single-screw extruder with a barrier screw and an L/D ratio of 25:1 is normally configured with barrel zones of 210 °C, 225 °C, 240 °C, 245 °C, and 250 °C, yielding a melt temperature of 245 ± 3 °C at the die entry. The unfilled Arkema Rilsan BMNO MED PA11 is dried in a desiccant dryer to a residual moisture content of <0.12 wt% and conveyed under a −40 °C dew-point air stream. The formulation addition ratio is 100 wt% BMNO MED for non-radiopaque catheter segments; if radiopacity is specified, a PA11-carrier BaSO₄ masterbatch is dry-blended at 15–30 wt%, with the 30 wt% upper limit imposed because higher loadings reduce tensile elongation at break and increase surface roughness in thin-wall tubing. The downstream process uses a vacuum sizer with closed-loop ultrasonic wall-thickness control, a 6 m water cooling trough at 16–22 °C, a draw-down ratio of 1.4:1 to 2.2:1, and in-line annealing at 130 °C for 3 h. Terminal finished product types include 0.9–1.3 mm OD microcatheter outer jackets, 2.5–3.0 mm diagnostic catheter shafts, and 6 Fr PICC catheter bodies. The applicable compliance standards are ISO 10555-1:2013 for intravascular catheter mechanical performance, ISO 10993-4:2017 for hemocompatibility, ISO 10993-5:2009 for cytotoxicity, USP <88> Class VI, and FDA 21 CFR Part 820 for quality systems. Gamma sterilization at 25–40 kGy is typical; exposure above 40 kGy without a stabilizer increases post-irradiation embrittlement risk, so elongation at break should be re-tested under ISO 527-2 after the maximum dose.

What Limits the Minimum Wall Thickness in Multi-Lumen Respiratory Gas Pathway Tubing?

Minimum wall thickness in a multi-lumen respiratory circuit tube is constrained by the melt strength of BMNO MED, the collapse resistance of the corrugated bellows, and the extractables control required under breathing gas pathway standards. On a triple-layer corrugated tubing line with a 45 mm extruder, barrel temperatures of 225–255 °C, die temperature of 240–245 °C, and a corrugator mold gap of 8–12 mm, the material is processed as 100 wt% unfilled BMNO MED with no external plasticizer and no carbon black. Where surface slip is required for automated cuff assembly, a silicone-free post-extrusion coating is applied at 0.5–1.0 g/m² rather than introducing a melt-phase lubricant, because melt additives can shift the extractables profile evaluated under ISO 10993-18:2020. The process uses a vacuum sizing tank at −0.05 MPa, a corrugator draw-off speed of 7–15 m/min, and annealing at 120 °C for 2 h. Terminal finished product types are non-invasive ventilation patient-circuit tubing, capnography sampling lines, and anesthesia breathing circuit segments. Compliance is anchored to ISO 18562-1:2017 for gas pathway biocompatibility, ISO 10993-18:2020 for leachables profiling, ISO 10993-5:2009 for cytotoxicity, and ISO 13485:2016 for manufacturing quality. Steam sterilization at 134 °C is generally avoided because the corrugated wall can collapse under internal vacuum and because repeated steam exposure accelerates hydrolytic degradation of the polyamide 11 backbone; ethylene oxide or low-temperature hydrogen peroxide plasma cycles are preferred, and post-sterilization leak and dimensional checks should be performed after every cycle.

In oral hygiene device manufacture, a 30 mm single-screw extruder with a 24:1 L/D metering screw and 20/40/60 mesh screen pack delivers BMNO MED to a 0.30 mm single-hole die at a melt temperature of 235 ± 5 °C. The formulation addition ratio is 100 wt% unfilled BMNO MED during extrusion; post-drawing, a microcrystalline wax dispersion is applied at 0.05–0.20 wt% pick-up for surface slip, and the monofilament is wound onto spools at 0.08–0.12 N tension. Downstream production involves a water quench bath at 20–30 °C, a first godet at 5 m/min, a second godet at 20–28 m/min for a draw ratio of 4.0:1 to 5.5:1, in-line hot-plate annealing at 140–150 °C, and final diameter control to 0.045–0.070 mm. Terminal finished product types are monofilament dental floss, orthodontic ligature filaments, and manual interdental brush stems. The applicable compliance standards are FDA 21 CFR 872.6400 for dental floss, ISO 16409:2006 for interdental brushes, ISO 10993-5:2009 for cytotoxicity, and ISO 10993-10:2010 for sensitization and irritation. If ambient relative humidity exceeds 60%, the resin must be dried at 85 °C for 12 h to bring the moisture content below 0.10 wt%; failure to do so produces diameter variability and microvoids that lower tensile strength under ISO 527-2.

Injection Molding Shrinkage and Crystallinity Control in Drug Delivery Actuators

Mold temperature and post-mold annealing are the two variables that determine whether a BMNO MED actuator component remains within the dimensional envelope required for metered-dose inhaler or auto-injector assembly. On an 8-cavity hot-runner mold with valve gates, the barrel profile is 220–255 °C, injection speed is 30–60 mm/s, holding pressure is 50–70 MPa, and mold temperature is 60–80 °C. The formulation addition ratio is 100 wt% BMNO MED for internal drug-path components; if color coding is specified for dose differentiation, a medical-grade masterbatch is added at 1–2 wt%, provided the colorant passes ISO 10993-18:2020 leachables testing. The resulting mold shrinkage is 0.8–1.2% in the flow direction and 0.7–1.0% transverse; post-mold annealing at 120 °C for 30 min stabilizes crystallinity and reduces birefringence in transparent components. Terminal finished product types are dry powder inhaler mouthpieces, press-and-breathe pMDI actuator bodies, auto-injector needle shields, and dose counter chassis. The applicable compliance standards are ISO 20072:2009 for aerosol drug delivery design verification, ISO 11608-1:2014 for needle-based injection systems, ISO 10993-5:2009, USP <88> Class VI, and ISO 13485:2016. A process limitation is that regrind is not used in drug-contact surfaces, because recycled material introduces uncontrolled molecular weight distribution and potential leachable oxidation products that fall outside the drug-device extractables profile.

Across multi-cavity luer connector production, the main processing conflict is between mold temperature sufficient to achieve a stable crystalline skin and gate pressure high enough to fill the thin luer taper without shear-induced discoloration. A four-cavity cold-runner mold with a heated sprue bushing and clamp force of 80–120 tonnes is operated with a barrel profile of 220–250 °C, mold temperature of 50–70 °C, and cycle time of 25–40 s. The formulation addition ratio is 100 wt% virgin BMNO MED with no regrind and no external silicone lubricant; if internal lubricity is required for stopcock rotation, a PTFE powder additive at 0.5–1.0 wt% may be compounded, but only after rotational torque and ISO 10993-5:2009 cytotoxicity tests are repeated. Post-mold annealing at 100 °C in a nitrogen-purged oven for 1 h reduces gate stress and stabilizes the luer taper diameter to the tolerance band required by ISO 80369-7:2016. Terminal finished product types are female and male Luer components, three-way stopcocks, IV extension-set hubs, and needleless access valve bodies. The applicable compliance standards are ISO 80369-7:2016, ISO 10993-5:2009, ISO 10993-10:2010, USP <88> Class VI, and FDA 21 CFR Part 820. If the taper surface is coated with silicone oil after molding, retention force can drop below the minimum specified in ISO 80369-7:2016; the design should therefore rely on the inherent low-friction surface of BMNO MED rather than post-mold lubricants.

Reusable surgical handpiece housings and clamp bodies are typically injection molded from BMNO MED when the device must survive low-temperature hydrogen peroxide plasma sterilization and repeated mechanical loading. The formulation addition ratio is 100 wt% BMNO MED, with a colored masterbatch at 1 wt% maximum if inventory colour coding is required; glass-fibre reinforcement is not used because fibre orientation in thin-wall sections causes anisotropic shrinkage and reduces elongation at break below the level needed for clip flexure. The downstream process uses a hot-runner mold at 60–80 °C, barrel temperatures of 220–255 °C, injection pressure of 70–90 MPa, cycle time of 35–50 s, and a post-bake at 120 °C for 2 h to reduce residual stress before ultrasonic welding at 20 kHz with an amplitude of 50–70 µm. Terminal finished product types are surgical clamp bodies, reusable instrument handles, biopsy device housings, and sterilizable tray brackets. The applicable compliance standards are ISO 17664-1:2021 for processing instructions, ISO 10993-5:2009 for cytotoxicity, ISO 10993-10:2010 for sensitization, USP <88> Class VI, and ISO 13485:2016. Steam autoclave exposure at 134 °C should be limited to fewer than 20 cycles because moisture uptake above 2.0 wt% softens the matrix and causes dimensional drift; hydrogen peroxide plasma or ethylene oxide is preferred. Published multicycle steam data for BMNO MED in load-bearing surgical clamps is limited; each manufacturer must validate dimensional stability after worst-case reprocessing according to ISO 17664-1:2021.